Lenalidomide-4-aminomethyl hydrochloride is primarily utilized in the field of pharmaceutical research and development, particularly in the synthesis of novel therapeutic agents. It serves as a key intermediate in the production of lenalidomide derivatives, which are known for their immunomodulatory and anti-cancer properties. This compound is often employed in the design and optimization of drugs targeting hematologic malignancies, such as multiple myeloma and myelodysplastic syndromes. Its role in enhancing the efficacy and specificity of these treatments makes it a valuable component in the development of advanced cancer therapies. Additionally, it is used in preclinical studies to explore its potential in modulating immune responses and inhibiting angiogenesis, further expanding its application in oncology and immunology research.